Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron receives R&D tax refund

Immuron receives R&D tax refund

Immuron (ASX:IMC) has received $1,469,763 in a cash refund from a Research & Development programs during 2015 in the form of tax concessions.

The Incentive refund is a tax concession for Australian biotechnology companies to fund ongoing research and development pipelines and advance promising programs.

Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea, while its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.

The company focuses on commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full IMC profile

Immuron Ltd Timeline

May 27 2016

Related Articles

September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Cancer cells
October 01 2016
Proactive takes a closer look at Vaxil, an Israeli bio-tech firm which listed in Toronto earlier this year. For investors, it could be a cheap way of getting into the exciting world of immunotherapy.
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.